STSandra Wingaard Thrane

Sandra Wingaard Thrane

*This is an algorithmically generated author record based on publicly available information.

Sandra Wingaard Thrane has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Validation of VHH-Binding Proteins as a Dietary Alternative to Pharmacological Zinc Oxide for the Control of Post-Weaning Diarrhoea in Piglets

    by Laia Ferreres-Serafini, David Solà-Oriol, Susana María Martín-Orúe, Marga Martín, Mercè Farré, Sandra Wingaard Thrane, Lorena Castillejos

    Post-weaning diarrhoea remains a major health and production challenge in pig farming, and effective alternatives to pharmacological zinc oxide are needed. This study evaluated bivalent VHH constructs as a potential dietary alternative to pharmacological zinc oxide under both controlled experimental and commercial production conditions. In Trial 1, 96 weaned piglets were orally challenged with enterotoxigenic Escherichia coli F4+ and received either a control diet, zinc-oxide-supplemented diet, or diet supplemented with bivalent VHH constructs. In Trial 2, 528 piglets were evaluated in a commercial nursery barn using the same dietary groups. In Trial 1, VHH supplementation improved post-challenge growth performance, reduced faecal EHEC counts and increased the lactobacilli-to-EHEC ratio, confirming previous evidence obtained under controlled conditions. Importantly, similar responses were observed under commercial conditions in Trial 2, where VHH-supplemented piglets showed improved faecal scores, higher average daily gain and greater final body weight. Quantile analysis further indicated that the positive response extended to the lower tail of the distribution of pen-level performance. These findings extend previous experimental evidence and demonstrate the efficacy of VHH supplementation under commercial production conditions, supporting its use as a nutritional alternative to pharmacological ZnO during the post-weaning period.

  • Open Access

    Genotoxicity, subchronic toxicity, and allergenicity evaluation of IgG Binding Protein CBB produced from Komagataella phaffii

    by Dayna Lozon, Kevin Scaife, Barry Lynch, Keal Gracey, Alica Šoltésová, Sandra Wingaard Thrane, Louise Kristine Vigsnæs, Signe Christensen, Rune Thorbjørn Nordvang, Nigel Baldwin, et al.

  • Open Access

    Controlled immobilization of single-domain antibodies using cellulose-binding modules for AB 5 -type toxin detection in paper-based assays

    by Selma B. Belfakir, Jonas A. Jürgensen, Marcus Petersson, Max Stæhr Wraae, Patrick Munk, Suthimon Thumtecho, Mateus G. Masteghin, Anne Ljungars, Andreas H. Laustsen, Sandra W. Thrane, et al.

    A single-domain antibody (VHH)-based sandwich-format lateral flow assay was developed for the detection of cholera toxin from V. cholerae and heat-labile enterotoxin from enterotoxigenic E. coli in human fecal and environmental water samples.


  • Open Access

    Attenuating ETEC virulence using a heat-labile enterotoxin–blocking binding protein

    by Marcus Petersson, Jens Sivkær Pettersen, Helena Bay Henriksen, Ágnes Duzs, Monica L. Fernández-Quintero, Nick Jean Burlet, Natalia Mojica, Ute Krengel, Timothy P. Jenkins, Andrew B. Ward, et al.

    Bacterial enteric pathogens are major contributors to the global burden of diarrheal diseases and the associated consequences for human health including malnutrition, growth stunting, morbidity, and mortality. While mortality from diarrhea has decreased, incidence remains high, and better interventions for preventing disease are needed. Single-domain antibodies (i.e., VHHs), functioning as target-binding proteins in the gastrointestinal tract, have been proposed as a potential approach to mitigate bacterial pathogenesis. Here, we describe a mitigation strategy where precision binding of a bivalent VHH to the receptor-binding B-pentamer of heat-labile enterotoxin aggregates the AB5 toxin and impairs enterotoxigenic Escherichia coli colonization in a flow chamber model simulating the human intestine. The VHH construct also binds to the structurally similar cholera toxin and effectively abrogates its intestinal cell cytotoxicity in vitro. Based on these results, we believe that targeting virulence could emerge as a new strategy for the management of bacterial enteric pathogens, supporting gut health in at-risk populations alongside vaccination campaigns or in populations without access to vaccines.


  • Open Access

    Allergenicity, Genotoxicity and Subchronic Toxicity Assessment of IgG Binding Protein LT Produced From Aspergillus oryzae

    by Kirt R. Phipps, Sachin Patel, Kevin Scaife, Toby Holmes, Alica Šoltésová, Sandra Wingaard Thrane, Louise Kristine Vigsnæs, Nigel Baldwin, Christel Jørgensen

    Gastrointestinal health is one of the fastest growing areas in the food and beverage industry, as its importance to overall health and well‐being is becoming increasingly recognized. Immunoglobulins play a key role in protecting the gastrointestinal tract, and nonbovine sources of immunoglobulins (including camel milk, which has a long history of consumption in East Africa and Asia) are increasing in popularity in Western countries as functional foods, particularly for individuals with allergies or intolerances to cow's milk. The physiological benefits of consuming certain heavy‐chain immunoglobulins from camel milk relate to the binding domains of camelid single‐domain antibodies; thus, a novel binding protein termed “immunoglobulin G (IgG) binding protein LT” (a dimer of two camelid single‐domain antibody protein sequences) has been developed for use in food and beverage products, to provide some of the physiological benefits attributed to consuming camel milk, on an industrial scale. To support the safety of IgG binding protein LT for such use, a comprehensive safety assessment (in silico allergenicity assessment, in vitro genotoxicity studies [bacterial reverse mutation test and in vitro mammalian cell micronucleus test], and a 90‐day gavage toxicity study in rats) was conducted. The in silico allergenicity assessment results demonstrate that IgG binding protein LT is highly unlikely to pose a risk of allergenic cross‐reactivity, and there was no evidence of genotoxicity in vitro. There were no test article–related effects in the 90‐day toxicity study. These data demonstrate the safety of IgG binding protein LT for its intended uses in foods and beverages.


  • Open Access

    Orally delivered toxin–binding protein protects against diarrhoea in a murine cholera model

    by Marcus Petersson, Franz G. Zingl, Everardo Rodriguez-Rodriguez, Jakob K. H. Rendsvig, Heidi Heinsøe, Emma Wenzel Arendrup, Natalia Mojica, Dario Segura Peña, Nikolina Sekulić, Ute Krengel, et al.

    The ongoing seventh cholera pandemic, which began in 1961, poses an escalating threat to public health. There is a need for new cholera control measures, particularly ones that can be produced at low cost, for the one billion people living in cholera-endemic regions. Orally delivered VHHs, functioning as target-binding proteins, have been proposed as a potential approach to control gastrointestinal pathogens. Here, we describe the development of an orally deliverable bivalent VHH construct that binds to the B-pentamer of cholera toxin, showing that it inhibits toxin activity in a murine challenge model. Infant mice given the bivalent VHH prior to V. cholerae infection exhibit a significant reduction in cholera toxin–associated intestinal fluid secretion and diarrhoea. In addition, the bivalent VHH reduces V. cholerae colonization levels in the small intestine by a factor of 10. This cholera toxin–binding protein holds promise for protecting against severe diarrhoea associated with cholera.


  • Open Access

    Fit‐for‐purpose heterodivalent single‐domain antibody for gastrointestinal targeting of toxin B fromClostridium difficile

    by Everardo R. Rodriguez Rodriguez, Rune Thorbjørn Nordvang, Marcus Petersson, Jakob Kræmmer Haar Rendsvig, Emma Wenzel Arendrup, Monica L. Fernández Quintero, Timothy P. Jenkins, Andreas H. Laustsen, Sandra Wingaard Thrane

    Single‐domain antibodies (sdAbs), such as VHHs, are increasingly being developed for gastrointestinal (GI) applications against pathogens to strengthen gut health. However, what constitutes a suitable developability profile for applying these proteins in a gastrointestinal setting remains poorly explored. Here, we describe an in vitro methodology for the identification of sdAb derivatives, more specifically divalent VHH constructs, that display extraordinary developability properties for oral delivery and functionality in the GI environment. We showcase this by developing a heterodivalent VHH construct that cross‐inhibits the toxic activity of the glycosyltransferase domains (GTDs) from three different toxinotypes of cytotoxin B (TcdB) from lineages ofClostridium difficile. We show that the VHH construct possesses high stability and binding activity under gastric conditions, in the presence of bile salts, and at high temperatures. We suggest that the incorporation of early developability assessment could significantly aid in the efficient discovery of VHHs and related constructs fit for oral delivery and GI applications.


  • Open Access

    Protecting the piglet gut microbiota against ETEC-mediated post-weaning diarrhoea using specific binding proteins

    by Timothy Patrick Jenkins, Norbert Ács, Emma Wenzel Arendrup, Abbie Swift, Ágnes Duzs, Ioanna Chatzigiannidou, Michael Pichler, Tiia Kittilä, Laura Peachey, Lone Gram, et al.

    Post-weaning diarrhoea (PWD) in piglets presents a widespread problem in industrial pig production and is often caused by enterotoxigenic E. coli (ETEC) strains. Current solutions, such as antibiotics and medicinal zinc oxide, are unsustainable and are increasingly being prohibited, resulting in a dire need for novel solutions. Thus, in this study, we propose and evaluate a protein-based feed additive, comprising two bivalent heavy chain variable domain (VHH) constructs (VHH-(GGGGS)3-VHH, BL1.2 and BL2.2) as an alternative solution to manage PWD. We demonstrate in vitro that these constructs bind to ETEC toxins and fimbriae, whilst they do no affect bacterial growth rate. Furthermore, in a pig study, we show that oral administration of these constructs after ETEC challenge reduced ETEC proliferation when compared to challenged control piglets (1-2 log10 units difference in gene copies and bacterial count/g faeces across day 2–7) and resulted in week 1 enrichment of three bacterial families (Prevotellaceae (estimate: 1.12 ± 0.25, q = 0.0054), Lactobacillaceae (estimate: 2.86 ± 0.52, q = 0.0012), and Ruminococcaceae (estimate: 0.66 ± 0.18, q = 0.049)) within the gut microbiota that appeared later in challenged control piglets, thus pointing to an earlier transition towards a more mature gut microbiota. These data suggest that such VHH constructs may find utility in industrial pig production as a feed additive for tackling ETEC and reducing the risk of PWD in piglet populations.


  • Open Access

    Orally delivered single-domain antibodies against gastrointestinal pathogens

    by Marcus Petersson, Sandra W. Thrane, Lone Gram, Serge Muyldermans, Andreas H. Laustsen


  • Open Access

    Orally active bivalent VHH construct prevents proliferation of F4+ enterotoxigenic Escherichia coli in weaned piglets

    by Berthe Katrine Fiil, Sandra Wingaard Thrane, Michael Pichler, Tiia Kittilä, Line Ledsgaard, Shirin Ahmadi, Grith Miriam Maigaard Hermansen, Lars Jelsbak, Charlotte Lauridsen, Susanne Brix, et al.